Page 24 - 《南京医科大学学报（自然科学版）》2025年第9期

第45卷第9期
·1236 · 南 京 医 科 大 学 学 报 2025年9月

T790M 阳性且既往 EGFR⁃TKI 进展的患者 ［16］ 。此 出良好疗效。然而，获得性耐药的出现是不可避免
外，奥希替尼作为 EGFR 突变的晚期非小细胞肺癌 的 ［17］ ，而耐药机制尚未完全阐明，因此了解奥希替
（non⁃small cell lung cancer，NSCLC）的一线治疗显示 尼获得性耐药的机制具有重要意义。

A B
1.5 HCC827/OR 1.5 H1975/OR H1975/OR HCC827/OR
*
*
Relative expression of hnRNPA1 1.0 Relative expression of hnRNPA1 1.0 si⁃NC si⁃hnRNPA1⁃1# si⁃hnRNPA1⁃2# si⁃NC si⁃hnRNPA1⁃1# si⁃hnRNPA1⁃2#
*
*
0.5
0.5
0 0 hnRNPA1 34 kDa
si⁃hnRNPA1⁃2#
si⁃hnRNPA1⁃2#
si⁃NC
si⁃hnRNPA1⁃1# si⁃hnRNPA1⁃1# β⁃actin 42 kDa
si⁃NC
C HCC827/OR H1975/OR
si⁃NC ** si⁃NC
1.2 1.5
** si⁃hnRNPA1 si⁃hnRNPA1
** **
1.0 si⁃NC+1.0 μmol/L Osimertinib si⁃NC+1.0 μmol/L Osimertinib
nm） 0.8 ** si⁃hnRNPA1+1.0 μmol/L nm） 1.0 si⁃hnRNPA1+1.0 μmol/L
Osimertinib
Osimertinib
（450 D 0.6 （450 D 0.5
0.4
0.2
0 0
0 24 48 72 96 0 24 48 72 96
Incubation time（h） Incubation time（h）
D HCC827/OR H1975/OR
si⁃NC
si⁃NC si⁃hnRNPA1 si⁃NC si⁃hnRNPA1
si⁃hnRNPA1
si⁃NC+1.0 μmol/L Osimertinib
μmol/L 250 si⁃hnRNPA1+1.0 μmol/L Osimertinib
0 200 ** * **
Osimertinib Number of colonies 150 ** * **
100
1.0 μmol/L 50 0 HCC827/OR H1975/OR

E HCC827/OR H1975/OR si⁃NC
si⁃hnRNPA1
si⁃NC si⁃hnRNPA1 si⁃NC si⁃hnRNPA1
si⁃NC+1.0 μmol/L Osimertinib
300 si⁃hnRNPA1+1.0 μmol/L
μmol/L * Osimertinib * *
*
Osimertinib 0 Number of cells 200 ** **

1.0 μmol/L
100
0
HCC827/OR H1975/OR
A：qRT⁃PCR was used to detect the knockdown efficiency of hnRNA1. B：Western blot was employed to assess the knockdown efficiency of hnRNA1.
C，D：The results of CCK8 and colony formation assays indicated that the proliferation ability of drug⁃resistant cells decreased after knockdown of hnRN⁃
*
**
PA1. E：The Transwell assay showed that the migration ability of drug⁃resistant cells declined after knockdown of hnRNPA1. P < 0.05 and P < 0.01（n=3）.
图6 hnRNPA1促进耐药细胞增殖迁移
Figure 6 hnRNPA1 promoted the proliferation and migration of drug⁃resistant cells